Every 10-Q that Celcuity Inc. (CELC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CELC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CELC filings page.
Celcuity Inc. reported a larger loss as it transitions from development toward commercialization of REVTORPYK (gedatolisib). For the quarter ended June 30, 2026, net loss was $78.9 million versus $45.3 million a year earlier, driven by sharply higher selling, general and administrative expenses of $35.0 million as the company built out its commercial infrastructure. Research and development expense declined to $31.1 million from $36.4 million.
Total assets rose to $828.2 million, including $754.0 million of cash, cash equivalents and short-term investments, after issuing $575.0 million of 0.250% convertible notes due 2032 and repaying its prior term loan. Convertible notes outstanding increased to $753.2 million, and stockholders’ equity moved to a deficit of $12.8 million, reflecting accumulated deficit of $580.6 million and new debt.
Subsequent to quarter-end, the FDA approved REVTORPYK for HR+/HER2- advanced breast cancer without a PIK3CA mutation, triggering a $50.0 million milestone payment to Pfizer that was recognized as an intangible asset and liability at June 30, 2026. Celcuity had used $110.5 million of cash in operating activities in the first half and believes its $754.0 million liquidity will fund operations for at least one year.
Celcuity Inc. reported a larger net loss as it ramps up late-stage development of its lead cancer drug gedatolisib. For the three months ended March 31, 2026, net loss was $52.8 million, compared with $37.0 million a year earlier, driven by higher research and development and commercial launch preparation costs.
Research and development expense rose to $33.1 million from $29.8 million, while selling, general and administrative expense increased to $17.4 million from $6.4 million as the company invested in marketing, market access and support functions ahead of potential commercialization. Celcuity ended the quarter with $387.1 million in cash, cash equivalents and short-term investments and stated this should fund operations for at least one year.
Strategically, the company highlighted strong Phase 3 VIKTORIA-1 results for gedatolisib in HR+/HER2- advanced breast cancer, including both PIK3CA wild-type and mutant cohorts, and ongoing Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials. The FDA accepted Celcuity’s New Drug Application for gedatolisib in PIK3CA wild-type disease, granted Priority Review, and set a PDUFA goal date of July 17, 2026, positioning the company for a potential first product approval.
Celcuity Inc. reported Q3 2025 results showing a larger net loss as it advanced late-stage oncology programs and expanded its balance sheet. For the quarter, the company recorded a net loss of $43.8 million and a nine‑month loss of $126.1 million, driven mainly by higher research and development spending of $34.9 million in Q3 and $107.4 million year to date.
To fund development, Celcuity strengthened liquidity. As of September 30, 2025, it held cash and cash equivalents of $74.3 million and U.S. Treasury bill investments of $380.7 million. During July 2025, it closed an equity offering with net proceeds of about $91.6 million and issued $201.3 million of 2.750% Senior Notes due 2031, raising net proceeds of roughly $194.9 million. Long‑term debt, including a term loan, totaled $125.2 million, and convertible debt was $195.1 million.
Clinically, Celcuity’s lead drug gedatolisib advanced meaningfully. The Phase 3 VIKTORIA‑1 trial in HR+/HER2‑ advanced breast cancer completed enrollment in both PIK3CA wild‑type and mutant cohorts, with cohort 1 showing a hazard ratio of 0.24 for progression‑free survival for a gedatolisib‑based triplet versus fulvestrant, indicating a 76% reduction in risk of progression or death. The company initiated dosing in the VIKTORIA‑2 Phase 3 first‑line trial and submitted the first portion of a New Drug Application for gedatolisib to the FDA under the Real‑Time Oncology Review program.
Celcuity Inc. reported interim financial details showing material financing and capital activity supporting its clinical programs. The company amended and restated a loan agreement that provided initial borrowings including Term A, B and C loans and contemplates additional tranches (Term D, Term E and optional Term F) tied to milestones and covenants; the Term Loans mature May 1, 2029 and bear variable interest with a portion payable in-kind. Innovatus has limited conversion and warrant rights tied to the loan.
Subsequent events include a completed equity offering of 1,836,842 shares and pre-funded warrants and the issuance of $201.25 million aggregate principal amount of 2.75% Convertible Senior Notes due 2031, generating approximately $194.9 million net proceeds. The company recognized a $5.0 million upfront license fee and issued $5.0 million in common stock to Pfizer and recorded a related R&D expense tied to an NDA filing deemed probable. Outstanding common shares increased to 38,914,208 as of June 30, 2025; no dividends were declared.